Medtech teams often have a development plan, a regulatory plan, a clinical plan and a commercial plan. The problem is that these plans are frequently built by different functions, at different times and around different assumptions.
An integrated medtech development roadmap makes those dependencies visible. It shows what must become true, what evidence will demonstrate it, which decisions depend on that evidence and how each work package changes technical, clinical, regulatory or commercial risk.
Start with the product definition
The roadmap should begin with a sufficiently clear product, not with a list of available activities. The intended use, users, care setting, workflow, claims and required performance define almost every downstream requirement.
If those elements remain vague, teams can make progress while moving in the wrong direction. Engineering may optimise the wrong specification. Clinical work may answer a question that does not support the claim. A regulatory strategy may be selected before the product and market assumptions are stable.
A practical starting point is a target product profile that describes:
- the unmet need and decision the product supports;
- the intended users, patients and settings;
- the proposed workflow and product configuration;
- the claims and performance required for value;
- the evidence, cost and implementation constraints.
Define value inflections, not only deliverables
A completed prototype, test report or study is a deliverable. A value inflection occurs when the result changes confidence in the product or business.
Examples include demonstrating that a performance threshold is achievable in the intended sample, confirming that the workflow is usable, resolving the regulatory classification, transferring a repeatable process or producing evidence that changes an NHS adoption decision.
Connect six critical paths
1. Product and engineering
Translate the target product profile into requirements, architecture, verification, usability and design-transfer work. Make technical dependencies and performance assumptions explicit.
2. Quality and regulatory
Map classification, markets, standards, quality-system needs, technical documentation and submission requirements onto the product and evidence plan.
3. Evidence
Connect each material claim to the analytical, technical, clinical and usability evidence needed to support it. Sequence studies so later spend depends on earlier evidence.
4. Manufacturing and supply
Bring suppliers, process capability, quality controls, design transfer, cost and scale into the roadmap before the development design becomes difficult to manufacture.
5. Commercialisation and adoption
Define the buyer, user, pathway, payment route and implementation barriers. Evidence for approval and evidence for adoption overlap, but they are not identical.
6. Finance and governance
Link funding tranches, partner decisions, board reviews and investment milestones to evidence and value inflections rather than optimistic dates.
Use decision gates with acceptance criteria
Each major phase should end with an explicit decision. Continue, amend, stop, redesign, narrow the claim, change partner or raise additional capital are all legitimate outcomes.
Define the evidence required, who owns the decision, the acceptable threshold, the consequence of failure and any residual uncertainty. This prevents a programme drifting forward because work has already started or money has already been spent.
Keep the roadmap alive
An integrated roadmap is a governance tool, not a one-off strategy document. It should change when evidence changes the assumptions. The discipline is to update the whole system, not only the workstream where the new information appeared.
That is the difference between a schedule and a credible critical path. The schedule says what the team intends to do. The critical path explains why the work is necessary, what it will prove and how it supports the product, company and next decision.